Rosiglitazone hepatotoxicity resulting from hepatic protein covalent binding derived from its aldehyde metabolite
Archives of Toxicology · 2026-08 · 100 (8) · 3667-3680
DOI: 10.1007/s00204-026-04382-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 13.05.2026. Verfasst von Yanjia Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China. Hauptthemen laut MEDLINE: Thiazolidinediones, Chemical and Drug Induced Liver Injury, Hypoglycemic Agents, Aldehydes. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Rosiglitazone (RGZ), a thiazolidinedione insulin sensitizer, is widely used in the treatment of type 2 diabetes mellitus. However, concerns regarding its dose-dependent hepatotoxicity have emerged, and the mechanisms of the toxic action remain elusive. This study aimed to investigate the mechanism by which an aldehyde metabolite generated through metabolic activation of RGZ forms covalent adduction with protein lysine residues and its contribution to hepatotoxicity. Using in vitro liver microsomal incubations coupled with LC-MS/MS, the reactive aldehyde metabolite and its corresponding lysine adduct were identified. It was verified that RGZ was primarily metabolized by CYP3A and CYP2E1 into an electrophilic aldehyde metabolite which subsequently underwent covalent bonding with the ε-amino group of lysine residues. The formation of the protein adduction was found to be associated with the hepatotoxicity of RGZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China.
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Educati…
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China. huzixia@syphu.edu.cn.
- Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China. yingpeng1999@163.com.
- Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China. zhengjiang@syphu.edu.cn.
ORCID-Profile: Jiang Zheng
Zitieren
APA
Zhao, Y., Yang, Y., Ding, Z., Sun, Y., Zhang, M., Li, W., Liu, T., Hu, Z., Peng, Y., & Zheng, J. (2026). Rosiglitazone hepatotoxicity resulting from hepatic protein covalent binding derived from its aldehyde metabolite. Archives of Toxicology, 100(8), 3667-3680. https://doi.org/10.1007/s00204-026-04382-3
Vancouver
Zhao Y, Yang Y, Ding Z, Sun Y, Zhang M, Li W, et al. Rosiglitazone hepatotoxicity resulting from hepatic protein covalent binding derived from its aldehyde metabolite. Archives of Toxicology. 2026;100(8):3667-3680. doi:10.1007/s00204-026-04382-3
BibTeX
@article{Zhao2026,
author = {Zhao, Yanjia and Yang, Yi and Ding, Zifang and Sun, Yao and Zhang, Mingyu and Li, Weiwei and Liu, Ting and Hu, Zixia and Peng, Ying and Zheng, Jiang},
title = {Rosiglitazone hepatotoxicity resulting from hepatic protein covalent binding derived from its aldehyde metabolite},
journal = {Archives of Toxicology},
year = {2026},
volume = {100},
number = {8},
pages = {3667--3680},
doi = {10.1007/s00204-026-04382-3}
}
EUVIMED